Posaconazole in the Prevention of COVID-19-associated Mucormycosis: A Concerning Contributor to the Rise in Antifungal Resistance.

IF 1.5

Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine Pub Date : 2021-10-01 DOI:10.5005/jp-journals-10071-23981

Bhavana Kayarat, Puneet Khanna

引用次数: 2

Abstract

How to cite this article: Kayarat B, Khanna P. Posaconazole in the Prevention of COVID-19-associated Mucormycosis: A Concerning Contributor to the Rise in Antifungal Resistance. Indian J Crit Care Med 2021;25(10):1209-1210.

查看原文本刊更多论文

泊沙康唑预防covid -19相关毛霉菌病:抗真菌耐药性上升的一个重要因素

泊沙康唑预防新冠肺炎相关毛霉菌病:抗真菌耐药性上升的一个令人担忧的因素。中华检验医学杂志;2009;25(10):1299 -1210。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine

自引率

0.00%

发文量